Eli Lilly and Company (NYSE:LLY) Shares Purchased by ERn Financial LLC

ERn Financial LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 57.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,364 shares of the company’s stock after acquiring an additional 495 shares during the period. ERn Financial LLC’s holdings in Eli Lilly and Company were worth $850,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares during the period. State Street Corp increased its position in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. State Street Corp now owns 33,878,417 shares of the company’s stock valued at $15,888,300,000 after acquiring an additional 642,274 shares during the period. Morgan Stanley boosted its holdings in Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after purchasing an additional 83,915 shares during the last quarter. Northern Trust Corp boosted its holdings in Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after purchasing an additional 355,317 shares during the last quarter. Finally, Norges Bank purchased a new stake in Eli Lilly and Company in the fourth quarter valued at $3,416,206,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.0 %

Shares of NYSE LLY traded down $0.22 during midday trading on Friday, reaching $777.96. 3,209,424 shares of the stock were exchanged, compared to its average volume of 2,972,386. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The stock has a market capitalization of $739.19 billion, a P/E ratio of 134.13, a PEG ratio of 1.71 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $334.58 and a twelve month high of $800.78. The company has a 50 day simple moving average of $734.06 and a 200 day simple moving average of $637.99.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the business posted $2.09 earnings per share. The business’s revenue was up 28.1% compared to the same quarter last year. As a group, equities analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on LLY. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Tuesday, February 20th. Finally, Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $689.52.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 34,538 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the transaction, the insider now owns 99,719,884 shares of the company’s stock, valued at $63,004,019,910.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 195,055 shares of company stock valued at $125,254,657 over the last quarter. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.